Loading stock data…
HBIO
$6.04+0.03 (+0.50%)
After Hours$6.04+0.00 (+0.00%)· Last close Jun 9
Harvard Bioscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harvard Bioscience, Inc. in the Healthcare sector is trading at $6.04 with a market capitalization of $27M. Wall Street consensus targets $6.00 (1 analysts), implying a -0.7% move over the next 12 months. The stock is currently 36% below its 52-week high of $9.40, remaining 6.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.04
Potential Downside
0%
Whystock Fair Value$6.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular techn...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.51
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.39%
Volume
Today's trading volume
16,517
Recent News
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...
Despite a slight dip in revenue, Harvard Bioscience Inc (HBIO) sees promising growth in new product lines and strategic initiatives.
Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary
Moby summary of Harvard Bioscience, Inc.'s Q1 2026 earnings call
How The Harvard Bioscience (HBIO) Investment Narrative Is Resetting After Lower 2026 Expectations
The latest update on Harvard Bioscience centers on a sharp reset in expectations, with the fair value estimate cut from US$2.00 to US$0.60. Analysts are using this lower target to reflect the revised 2026 revenue estimate of US$89.2m and a more cautious view on how long a recovery in the business might take. As you read on, you will see how these shifting views are shaping the current narrative and what to watch to stay on top of future updates. Analyst Price Targets don't always capture the...
Harvard Bioscience Inc (HBIO) Q4 2025 Earnings Call Highlights: Strong Operational Efficiency ...
Despite a challenging year, Harvard Bioscience Inc (HBIO) showcases robust EBITDA growth and strategic plans for future expansion.
Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary
Moby summary of Harvard Bioscience, Inc.'s Q4 2025 earnings call